Trial Profile
A Phase 2, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Varlitinib (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Biomarker; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 16 May 2020 The trial has been discontinued in Poland according to European Clinical Trials Database record.
- 21 May 2018 Planned initiation date changed from 1 Jul 2017 to 1 May 2018.
- 21 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.